Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology's Annual Scientific Session.

Related Keywords

Minnesota ,United States ,New York ,China ,Kunshan ,Fujian ,Chinese , ,Chinese Society Of Cardiology ,Icahn School Of Medicine At Mount Sinai ,Yung Shin Pharmaceutical Industrial Co ,Shenzhen Salubris Pharmaceuticals Co Ltd ,Medtronic Corp ,American College Of Cardiology ,American College Of Cardiology Annual Scientific Session ,National Natural Scientific Foundation Of China ,American College ,Annual Scientific ,Icahn School ,Mount Sinai ,Chinese Society ,National Natural Scientific Foundation ,Jiangsu Provincial ,Nanjing Municipal Clinical Trial ,Microport Medical ,Yung Shin Pharmaceutical Industrial ,Aspirin ,Bleeding ,Flood ,Ardiology ,Chest Pain ,Drugs ,Efficacy ,Heart ,Heart Attack ,Rain ,Placebo ,